Suppr超能文献

新型癌抑素类似物通过 JNK 激活和 STAT3 抑制发挥抗肿瘤活性。

Antitumor activity of a novel oncrasin analogue is mediated by JNK activation and STAT3 inhibition.

机构信息

Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.

出版信息

PLoS One. 2011;6(12):e28487. doi: 10.1371/journal.pone.0028487. Epub 2011 Dec 12.

Abstract

BACKGROUND

To optimize the antitumor activity of oncrasin-1, a small molecule identified through synthetic lethality screening on isogenic K-Ras mutant tumor cells, we developed several analogues and determined their antitumor activities. Here we investigated in vitro and in vivo antitumor activity of NSC-743380 (1-[(3-chlorophenyl) methyl]-1H-indole-3-methanol, oncrasin-72), one of most potent analogues of oncrasin-1.

METHODOLOGY AND PRINCIPAL FINDINGS

In vitro antitumor activity was determined in NCI-60 cancer cell line panel using cell viability assay. In vivo antitumor activity was determined in parallel with NSC-741909 (oncrasin-60) in xenograft tumors established in nude mice from A498, a human renal cancer cell line. Changes in gene expression levels and signaling pathway activities upon treatment with NSC-743380 were analyzed in breast and renal cancer cells by Western blot analysis. Apoptosis was demonstrated by Western blot analysis and flow cytometric analysis. NSC-743380 is highly active against a subset of cancer cell lines derived from human lung, colon, ovary, kidney, and breast cancers. The 50% growth-inhibitory concentration (GI(50)) for eight of the most sensitive cell lines was ≤ 10 nM. In vivo study showed that NSC-743380 has a better safety profile and greater antitumor activity than NSC-741909. Treatment with NSC-743380 caused complete regression of A498 xenograft tumors in nude mice at the tested doses ranging from 67 mg/kg to 150 mg/kg. Mechanistic characterization revealed that NSC-743380 suppressed the phosphorylation of C-terminal domain of RNA polymerase II, induced JNK activation, inhibited JAK2/STAT3 phosphorylation and suppressed cyclin D1 expression in sensitive human cancer cells. Blocking JNK activation or overexpression of constitutively active STAT3 partially blocked NSC-743380-induced antitumor activity.

CONCLUSIONS

NSC-743380 induces antitumor activity through modulation of functions in multiple cancer related pathways and could be a potential anticancer agent for some solid tumors.

摘要

背景

为了优化 oncrasin-1 的抗肿瘤活性,我们通过对同源 K-Ras 突变肿瘤细胞进行合成致死筛选,开发了几种类似物,并确定了它们的抗肿瘤活性。在这里,我们研究了 oncrasin-72(1-[(3-氯苯基)甲基]-1H-吲哚-3-甲醇),oncrasin-1 的一种最有效的类似物之一,在体外和体内的抗肿瘤活性。

方法和主要发现

使用细胞活力测定法在 NCI-60 癌症细胞系组中测定体外抗肿瘤活性。在裸鼠中建立 A498(人肾癌细胞系)异种移植肿瘤的同时,用 NSC-741909(oncrasin-60)进行体内抗肿瘤活性测定。通过 Western blot 分析分析了处理 NSC-743380 后乳腺癌和肾癌细胞中基因表达水平和信号通路活性的变化。通过 Western blot 分析和流式细胞术分析证明了细胞凋亡。NSC-743380 对源自人肺、结肠、卵巢、肾和乳腺的癌症细胞系具有高度活性。八种最敏感细胞系的 50%生长抑制浓度(GI(50))≤10 nM。体内研究表明,与 NSC-741909 相比,NSC-743380 具有更好的安全性和更大的抗肿瘤活性。在测试剂量为 67mg/kg 至 150mg/kg 时,NSC-743380 可使 A498 异种移植肿瘤在裸鼠中完全消退。机制特征表明,NSC-743380 抑制 RNA 聚合酶 II C 末端结构域的磷酸化,诱导 JNK 激活,抑制 JAK2/STAT3 磷酸化并抑制敏感人癌细胞中环素 D1 的表达。阻断 JNK 激活或过表达组成型激活的 STAT3 部分阻断了 NSC-743380 诱导的抗肿瘤活性。

结论

NSC-743380 通过调节多个与癌症相关的通路中的功能诱导抗肿瘤活性,可能成为某些实体瘤的潜在抗癌药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/943f/3236185/4a572a469b6f/pone.0028487.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验